Compounds > fertirelin
Page last updated: 2024-09-26

fertirelin

Description

fertirelin: analog of luteinizing hormone releasing factor; more potent than LHFSHRH; RN given is for releasing factor from pig; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID188304
CHEMBL ID3272563
CHEBI ID177856
MeSH IDM0055054

Synonyms (32)

Synonym
CHEBI:177856
fertirelin acetate
fertirelin
38234-21-8
fertirelin (inn)
D07957
A824075
q041ao6t91 ,
fertireline
fertirelinum [inn-latin]
fertirelinum
fertireline [inn-french]
unii-q041ao6t91
9-(n-ethyl-l-prolinamide)-10-deglycinamide
fertirelina [inn-spanish]
fertirelin [inn:ban]
fertirelina
AKOS015896030
tap 031
tap-031
CHEMBL3272563
cas-38234-21-8
dtxcid9031517
dtxsid8057728 ,
tox21_113925
NCGC00262930-01
gtpl9341
Q27286835
F85427
MS-32015
1-9-luteinizing hormone-releasing factor (swine),9-(n-ethyl-l-prolinamide)-
AC-8920

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency26.83700.01237.983543.2770AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1148724Agonist activity at LH-RH receptor (unknown origin) relative to LH-RH1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Inhibitors of the luteinizing hormone-releasing hormone based upon modifications in the 2, 3, and 6 positions.
AID1346002Human GnRH1 receptor (Gonadotrophin-releasing hormone receptors)2016British journal of pharmacology, Jan, Volume: 173, Issue:1
Characterization of 12 GnRH peptide agonists - a kinetic perspective.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (28.57)18.7374
1990's12 (24.49)18.2507
2000's9 (18.37)29.6817
2010's8 (16.33)24.3611
2020's6 (12.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (4.08%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.04%)4.05%
Observational0 (0.00%)0.25%
Other46 (93.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
ay 25,205[no description available]medium20
buserelin[no description available]medium20oligopeptide
deslorelin[no description available]medium10oligopeptide
estradiol 3-benzoate[no description available]medium2017beta-hydroxy steroid;
benzoate ester		estrogen receptor agonist;
xenoestrogen
cloprostenol[no description available]medium31prostanoid
dinoprost tromethamine[no description available]medium10organic molecular entity
dinoprost[no description available]medium50monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
17-alpha-hydroxyprogesterone[no description available]medium1017alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
tertiary alpha-hydroxy ketone		human metabolite;
metabolite;
mouse metabolite;
progestin
leuprolide[no description available]medium20oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
lhrh(5-10), ac-[no description available]medium10
fenprostalene[no description available]medium10
beta-endorphin[no description available]medium10
morphine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
delprostenate[no description available]medium10
goralatide[no description available]low00oligopeptide;
tetrapeptide		anti-inflammatory agent;
pro-angiogenic agent
posatirelin[no description available]low00oligopeptide
amogastrin[no description available]low00oligopeptide
phenylalanyl-phenylalanyl-phenylalanine[no description available]low00oligopeptide
methionyl-leucyl-phenylalanine[no description available]low00oligopeptide
msh release-inhibiting hormone[no description available]low00oligopeptide
alanyl-glycyl-glycine[no description available]low00oligopeptide
glycyl-leucyl-tyrosine[no description available]low00oligopeptide
prolyl-glycyl-glycine[no description available]low00oligopeptide
glycyl-histidyl-glycine[no description available]low00oligopeptide
arginyl-glycyl-aspartic acid[no description available]low00oligopeptide
bradykinin, des-arg(9)-[no description available]low00oligopeptidebradykinin receptor B2 agonist
s-ethyl glutathione[no description available]low00oligopeptide
enkephalin, ser(2), leu(5), thr(6)-[no description available]low00oligopeptide
ta 0910[no description available]low00oligopeptideanalgesic;
neuroprotective agent;
nootropic agent
morphiceptin[no description available]low00oligopeptide
arg-3-hyp-7-phe-bradykinin[no description available]low00oligopeptidebradykinin receptor antagonist
splenopentin[no description available]low00oligopeptide
pyroglutamyl-glutamyl-proline amide[no description available]low00oligopeptide
cgp 42112a[no description available]low00benzyl ester;
oligopeptide;
pyridinecarboxamide		angiotensin receptor agonist;
anti-inflammatory agent;
antineoplastic agent;
neuroprotective agent;
vasodilator agent
glycyl-glycyl-cysteine[no description available]low00oligopeptide
msh (11-13)[no description available]low00oligopeptide
rigin[no description available]low00oligopeptide
glycyl-leucyl-phenylalanine[no description available]low00oligopeptide
hemorphin 4[no description available]low00oligopeptide
splenotritin[no description available]low00oligopeptide
leucyl-aspartyl-valine[no description available]low00oligopeptide
seryl-lysyl-leucine[no description available]low00oligopeptide
diprotin b[no description available]low00oligopeptide
kinetensin[no description available]low00oligopeptidehistamine releasing agent;
human metabolite
lysyl-tyrosyl-lysine[no description available]low00oligopeptide
phenylalanyl-phenylalanyl-glycine[no description available]low00oligopeptide
prolyl-prolyl-glycine[no description available]low00oligopeptide
ustiloxin d[no description available]low00oligopeptide
lysyl-tryptophyl-alpha-lysine[no description available]low00oligopeptide
pentigide[no description available]low00oligopeptide
rhizonin a[no description available]low00oligopeptide
bradykinin, des-phe(8)-des-arg(9)-[no description available]low00oligopeptidehuman metabolite;
rat metabolite
prolyl-leucyl-glycine[no description available]low00oligopeptide
bradykinin, hydroxy-pro(3)-[no description available]low00oligopeptide;
peptide hormone		bradykinin receptor agonist;
human urinary metabolite
glycyl-prolyl-arginine[no description available]low00oligopeptide
kentsin[no description available]low00oligopeptide
cadystin protein, s pombe[no description available]low00oligopeptide;
phytochelatin
cilengitide[no description available]low00oligopeptide
s-benzoylmercaptoacetyltriglycine[no description available]low00oligopeptide
glycyl-glycyl-valine[no description available]low00oligopeptide
bradykinin[no description available]low00oligopeptidehuman blood serum metabolite;
vasodilator agent
elastin[no description available]low00oligopeptide
phenylalanyl-prolyl-arginine[no description available]low00oligopeptide
thymopentin[no description available]low00oligopeptide
gonadotropin-releasing hormone[no description available]low00oligopeptide;
peptide hormone		gonadotropin releasing hormone agonist
telaprevir[no description available]low00cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
rgh 0205[no description available]low00oligopeptide
leucyl-prolyl-proline[no description available]low00oligopeptide
glycyl-prolyl-glutamic acid[no description available]low00oligopeptide
spinorphin[no description available]low00oligopeptide
trimethionine[no description available]low00oligopeptide
cyclo(d-tyrosyl-arginyl-arginyl-3-(2-naphthyl)alanyl-glycyl)[no description available]low00oligopeptide
atosiban[no description available]low00oligopeptide
endomorphin 1[no description available]low00oligopeptide
l796778[no description available]low00benzenes;
C-nitro compound;
L-lysine derivative;
L-phenylalanine derivative;
methyl ester;
oligopeptide;
secondary carboxamide;
ureas		somatostatin receptor agonist
dermorphin[no description available]low00oligopeptide
saralasin[no description available]low00oligopeptide
phomopsin[no description available]low00oligopeptide
montirelin[no description available]low00oligopeptide
icatibant[no description available]low00oligopeptidebeta-adrenergic antagonist;
bradykinin receptor antagonist;
peptidomimetic
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone[no description available]low00oligopeptide
glycyl-alanyl-phenylalanine[no description available]low00oligopeptide
diglycyl-histidine[no description available]low00oligopeptide
davunetide[no description available]low00oligopeptide
sincalide[no description available]low00oligopeptide
p 829[no description available]low00oligopeptide
bremelanotide[no description available]low00oligopeptide
isoleucyl-prolyl-proline[no description available]low00oligopeptide
angiotensin amide[no description available]low00oligopeptide
arginyl-glycyl-serine[no description available]low00oligopeptide
phakellistatin 13[no description available]low00oligopeptide
isoleucyl-valyl-tyrosine[no description available]low00oligopeptide
ulimorelin[no description available]low00oligopeptide
glycyl-prolyl-hydroxyproline[no description available]low00oligopeptide
bms-650032[no description available]low00oligopeptide
ceruletide[no description available]low00oligopeptidediagnostic agent;
gastrointestinal drug
teicoplanin aglycone[no description available]low00oligopeptide
s-(2-chloroethyl)glutathione[no description available]low00oligopeptide
cetrorelix[no description available]low00oligopeptideantineoplastic agent;
GnRH antagonist
nafarelin[no description available]low00oligopeptideanti-estrogen;
gonadotropin releasing hormone agonist
histrelin[no description available]low00oligopeptideantineoplastic agent;
gonadotropin releasing hormone agonist
apelin-13 peptide[no description available]low00oligopeptideantihypertensive agent;
autophagy inhibitor;
biomarker;
human metabolite;
neuroprotective agent
arginyl-glycyl-glutamic acid[no description available]low00oligopeptide
callipeltin a[no description available]low00cyclodepsipeptide;
guanidines;
lactone;
oligopeptide;
phenols		anti-HIV-1 agent;
antifungal agent;
metabolite
lysyl-glutamyl-aspartic acid[no description available]low00oligopeptide
gamma-glutamylfelinylglycine[no description available]low00oligopeptide
alanyl-glutamyl-aspartic acid[no description available]low00oligopeptide
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide[no description available]low00aldehyde;
indolecarboxamide;
oligopeptide;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
apelin-12 peptide[no description available]low00oligopeptidebiomarker;
human blood serum metabolite;
human metabolite;
neuroprotective agent
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide[no description available]low00aldehyde;
indolecarboxamide;
monofluorobenzenes;
oligopeptide;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Abdominal Cryptorchidism0low10
Aging0low10
Bilateral Cryptorchidism0low10
Bovine Diseases0low40
Canine Diseases0low20
Cattle Diseases0low40
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Corpus Luteum Cyst0low30
Cryptorchidism0low10
Cryptorchidism, Unilateral Or Bilateral0low10
Cryptorchism0low10
Disease Models, Animal0low10
Dog Diseases0low20
Dystocia0low10
Fever, Zika0low10
Hypothermia0low10
Hypothermia, Accidental0low10
Infertility, Female0low10
Inguinal Cryptorchidism0low10
Ovarian Cysts0low30
Placenta Diseases0low10
Placenta Disorders0low10
Placental Diseases0low10
Pregnancy0medium131
Puerperal Disorders0low10
Sterility, Female0low10
Sterility, Postpartum0low10
Sub-Fertility, Female0low10
Subfertility, Female0low10
Testes, Undescended0low10
Testis, Undescended0low10
Undescended Testis0low10
Unilateral Cryptorchidism0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Bioavailability (1)

ArticleYear
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (1)

ArticleYear
Inhibitors of the luteinizing hormone-releasing hormone based upon modifications in the 2, 3, and 6 positions.
Journal of medicinal chemistry, Volume: 19, Issue: 2		1976
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]